AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01932073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
Study NCT02434367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk With Ease Arm A
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
Study NCT02164773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
Study NCT02164773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%normal saline
Description: use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
Study NCT00126607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00126607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00957112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: acupuncture therapy
Description: Patients undergo therapist-acupuncture with or without self-acupuncture
Study NCT00957112 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: standard follow-up care
Description: Patients receive standard care
Study NCT00614328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone, Baclofen, Placebo and Behavior Therapy
Description: Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
Study NCT00614328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Naltrexone, Baclofen, Placebo and Behavior Therapy
Description: Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
Study NCT03579576 — intervention group
Intervention type: DRUG
Intervention: sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.
Description: Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.
Study NCT04350606 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06462700
Description: PF-06462700 is classified as an immunosuppressant/ immunosuppressive agent. It is the purified, concentrated, and sterile gamma globulin, primarily monomeric immunoglobulin G (IgG), from hyperimmune serum of horses that are immunized with human thymus lymphocytes.
Study NCT02499978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir/Cobicistat
Description: Fixed dose combination medication
Study NCT02499978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/Cobicistat
Description: Fixed dose combination medication
Study NCT02499978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: single tablet medication
Study NCT02499978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: single tablet medication
Study NCT01842815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 755 nm alexandrite laser
Description: 755 nm alexandrite laser for the treatment of unwanted, non cosmetic, tattoos.
Study NCT00292318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study
Description: Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
Study NCT03150368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ModraDoc006/r
Description: Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
Study NCT03882463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring with the stop insulin pump function
Description: Children with type 1 diabetes using insulin pump and continuous glucose monitoring without the stop insulin pump functionare then using the predictive system for stopping before hypoglycaemia medtronic Minimed with SmartGuard technology.
Study NCT00928109 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBCT
Description: Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
Study NCT00928109 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Supportive Therapy
Description: Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
Study NCT03853499 — intervention group
Intervention type: OTHER
Intervention: No intervention (observational study)
Description: No intervention (observational study)
Study NCT01304147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: A single dose of intranasal ketamine up to 50 mg
Study NCT01304147 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Single dose of saline intranasal
Study NCT02229682 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Mild-dose IMRT
Description: IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
Study NCT00292318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: Medical counseling and ano-sphinctal exercises.
Study NCT03221907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR GLARS-NF1
Description: Pregabalin tablet
Study NCT03221907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLA5PR GLARS-NF1 placebo
Description: tablet manufactured to mimic GLA5PR GLARS-NF1
Study NCT03221907 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Pregabalin capsule
Study NCT03221907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin placebo
Description: tablet manufactured to mimic pregabalin capsule
Study NCT00719095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine taper followed by naltrexone maintenance
Description: direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
Study NCT00719095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Study NCT04560790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BD111 Adult single group Dose
Description: 3-6 Participants will receive a single group dose administered via corneal injection in the study eye.
Study NCT01464944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
Study NCT01464944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (Aspirin, BAYE4465)
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
Study NCT01464944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
Study NCT01464944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
Study NCT01464944 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
Study NCT02462629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BLZ-100
Study NCT01877278 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wearable pulsed electromagnetic fields
Study NCT00759200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 900 mcg every 4 weeks
Study NCT00759200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 1200 mcg every 4 weeks
Study NCT00759200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 1500 mcg every 4 weeks
Study NCT00759200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alb-interferon alfa 2b
Description: 1800 mcg every 4 weeks
Study NCT00759200 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peg-interferon
Description: Peg-interferon alfa 2a: 180 mcg 1x per wk.
Study NCT04332276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-dopamine
Description: During the phase 1 (titration), it is planned to increase dopamine by maximum 0.25 mg per hour over the daytime period, which corresponds to a maximum increase of 4.5 mg per day (based on the 18 hours of the daytime period, since nocturnal needs are much less important).~Then, depending on tolerance and efficacy, conservative titration will be continued for a target dose of 30-87 mg per day.~During the phase 2 (efficacy), the treatment will be maintained at the minimum effective dose, planned between 30 and 87 mg per day, for 30 days.
Study NCT04332276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: optimized oral treatment
Description: The patient will received his usual dopaminergic treatment.
Study NCT01877278 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wearable pulsed electromagnetic fields
Study NCT00674063 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alefacept
Description: IV
Study NCT00771316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0826 (ertapenem)
Description: A single dose of 1.0g IV infused over a 30 minute interval at hour 0
Study NCT01157598 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bispectral index monitoring
Description: parameter monitoring of bispectral index
Study NCT01157598 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: bispectral index monitoring
Description: parameter monitoring of bispectral index
Study NCT05586386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cherry group
Description: 200 mL of DSC juice twice/day supplemented with 3g of DSC powder twice/day for 30 days
Study NCT05586386 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo group
Description: 200 mL of placebo juice twice/day
Study NCT05701124 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab (0.25 mg/0.025 mL)
Description: Intravitreal injection (IVI) was performed under topical anesthesia in standard ophthalmic operating room. 5% povidone-iodine disinfection and topical antibiotic were instilled. Ranibizumab (0.25 mg/0.025 mL) was injected into the vitreous cavity with a 31-gauge needle, aiming the needle directly toward the optic nerve in direction of visual axis 1.0 mm posterior to the corneoscleral junction at the inferotemporal quadrant. The intraocular pressure and central artery perfusion were then checked.
Study NCT00771316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: meropenem
Description: 500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
Study NCT00602667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction Chemotherapy
Description: All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
Study NCT00842803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin infusion (25% albumin)
Description: Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
Study NCT04351672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Feeding
Description: Eat between 8 am and 4 pm for two weeks
Study NCT04351672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Time-Restricted Feeding
Description: Eat between 1 pm and 9 pm for two weeks
Study NCT03378635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasiglucagon
Description: Glucagon analog
Study NCT03378635 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen
Description: Native glucagon
Study NCT00602667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Risk Therapy
Description: Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
Study NCT03378635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for dasiglucagon
Study NCT00602667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Risk Therapy
Description: High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
Study NCT02301793 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse education in contemporary format
Description: Education about VTE was delivered through a web-based contemporary interactive format
Study NCT02301793 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nurse education in traditional format
Description: Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
Study NCT00602667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermediate-Risk Therapy
Description: Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).~Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan.
Study NCT03118973 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Goff trans-pancreatic septotomy vs. Double wire technique
Description: Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
Study NCT00648713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets 250 mg
Description: 250mg, single dose fed
Study NCT00648713 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamisil® Tablets 250 mg
Description: 250mg, single dose fed
Study NCT01292993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400 mg LX4211
Description: 400 mg of LX4211 given as a solid oral dose form
Study NCT03109054 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: State-Trait Anxiety Inventory Test
Description: All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
Study NCT01292993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1000 mg metformin
Description: 1000 mg metformin given as a solid oral dose form
Study NCT04052282 — intervention group
Intervention type: DEVICE
Intervention: Mobile Health App
Description: There is no intervention
Study NCT04195256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN Ketodex (D4K2)
Description: Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
Study NCT04195256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN Ketodex (D3K3)
Description: Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
Study NCT04195256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IN Ketodex (D2K4)
Description: Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
Study NCT04195256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Ketamine
Description: Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares
Study NCT00945997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
Study NCT00945997 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
Study NCT03171051 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 950 nm LED Device
Description: Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
Study NCT03171051 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 1050nm Diode Laser Device
Description: FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
Study NCT03885440 — intervention group
Intervention type: OTHER
Intervention: Age
Description: Age\<40 years old is chosen as the cutoff value.
Study NCT03885440 — intervention group
Intervention type: OTHER
Intervention: OSA
Description: The diagnosis of OSA (obstructive sleep apnea) relies on polysomnographic data showing an apnea-hypopnea index at least 5/hr with compatible symptoms.
Study NCT00445978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin Dihydrochloride
Description: Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) sapropterin dihydrochloride during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Dosing was with 100 mg tablets and rounded to the nearest whole tablet. Each dose was taken within 1 hour after the morning meal. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
Study NCT02378623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (\<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.